While Al-Janabi et al did not specifically investigate the antimetastatic potential of their TAM-targeted therapy, other studies have demonstrated the systemic effects of STING or TLR agonists.5 6 Of note, the intratumoral administration of poly(I:C) and R848 induced long-term activation of innate and adaptive immune responses (CD4 and CD8 T cells), leading to systemic antitumor activity, elimination of metastatic cancer cells, and rejection of tumor rechallenge. Here, STING1 is linked to cancer.